Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Long-Term Investments (2018 - 2025)

BioNexus Gene Lab's Long-Term Investments history spans 8 years, with the latest figure at $2.0 million for Q4 2025.

  • Quarterly results put Long-Term Investments at $2.0 million for Q4 2025, up 60.26% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 60.26% YoY), and the annual figure for FY2025 was $2.0 million, up 60.26%.
  • Long-Term Investments for Q4 2025 was $2.0 million at BioNexus Gene Lab, up from $237760.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $2.0 million in Q4 2025 to a low of $237760.0 in Q3 2025.
  • The 5-year median for Long-Term Investments is $1.2 million (2023), against an average of $1.2 million.
  • The sharpest move saw Long-Term Investments surged 35579.89% in 2021, then crashed 88.08% in 2025.
  • Year by year, Long-Term Investments stood at $749027.0 in 2021, then skyrocketed by 53.65% to $1.2 million in 2022, then surged by 47.7% to $1.7 million in 2023, then fell by 25.57% to $1.3 million in 2024, then surged by 60.26% to $2.0 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $2.0 million, $237760.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.